Teodosio Rucabado Bruno
Cardiovascular Disease · San Juan, PRNPI 1801907233
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,971 of the $9,759 with a category attached, or 81.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,057 and has fallen 81.4% since, to $755 in 2025.
Across 115 payments — averaging $84.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Boston Scientific$1K
- Boehringer Ingelheim$943
- Abbott$889
- Amgen$834
- Bayer$612
- plus $3K from 16 others
What the payments were for
- Consulting fees$1,75018%
- Food & beverage$7,97182%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $1,842 |
| Boston Scientific | 13 | $1,456 |
| Boehringer Ingelheim | 13 | $943 |
| Abbott | 11 | $889 |
| Amgen | 8 | $834 |
| Bayer | 6 | $612 |
| United Therapeutics Corporation | 10 | $455 |
| AstraZeneca | 5 | $382 |
| Medtronic(2 entities) | 5 | $331 |
| Johnson & Johnson | 6 | $270 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $270 |
| Actelion Pharmaceuticals US, Inc. | 3 | $255 |
| E.r. Squibb & Sons, L.L.C. | 5 | $226 |
| PBG Puerto Rico LLC | 8 | $194 |
| Pfizer Pharmaceuticals LLC | 1 | $125 |
| GSK | 1 | $121 |
| Novartis | 2 | $118 |
| Edwards Lifesciences | 1 | $115 |
| Mallinckrodt Hospital Products Inc. | 1 | $114 |
| Merck | 1 | $100 |
| AbbVie | 5 | $90 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$1,875
- JARDIANCE$729
- Adempas$598
- WATCHMAN FLX$470
- ORENITRAM$440
- Repatha$362
- GALLANT$230
- Watchman$213
- LifeVest$200
- LUX-Dx Insertable Cardiac Monitor$144
- EMBLEM MRI S-ICD$138
- NA$136
- Otezla$125
- SYNERGY$125
- Ensite Cardiac Mapping System$123
- BENLYSTA$121
- SAPHNELO$119
- KRYSTEXXA$119
- FARXIGA$118
- UPTRAVI$118
How this compares
$9,759 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 103 | $73,729 |
| EliquisApixaban | 99 | $71,021 |
| EntrestoSacubitril/Valsartan | 51 | $44,884 |
| XareltoRivaroxaban | 47 | $31,167 |
| FarxigaDapagliflozin Propanediol | 33 | $27,182 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 121 | $12,725 |
| Repatha PushtronexEvolocumab | 20 | $12,232 |
| Candesartan Cilexetil | 125 | $10,939 |
| BrilintaTicagrelor | 22 | $9,777 |
| Atorvastatin Calcium | 658 | $7,061 |
| Metoprolol Succinate | 356 | $5,165 |
| Rosuvastatin Calcium | 338 | $4,554 |
| Losartan Potassium | 441 | $4,206 |
| Carvedilol | 338 | $2,979 |
| Irbesartan | 87 | $2,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $943 | $73,729103 claims |
| PfizerEliquis | $1,842 | $71,02199 claims |
| NovartisEntresto | $118 | $44,88451 claims |
| AstraZenecaFarxiga, Brilinta | $382 | $36,95955 claims |
| Johnson & JohnsonXarelto | $270 | $31,16747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in San Juan
- Manuel GuzmanSan Juan$203K
- Ramon PereaSan Juan$68K
- Francisco Merced-OrtizSan Juan$54K
- Sonia VicentySan Juan$23K
- Sonia Velazquez-NavarroSan Juan$17K
- Pedro Vargas-OteroSan Juan$15K
- Ricardo ColacioppoSan Juan$14K
- Jose Kareh CorderoSan Juan$13K
- William Borges CancelSan Juan$13K
- Zuanette Ramos-RoblesSan Juan$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.